Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter CCR4 (Mogamulizumab Biosimilar) Antikörper

Reaktivität: Human Dep Wirt: Kaninchen Chimeric KW-0761 unconjugated Recombinant Antibody
Produktnummer ABIN7072382
  • Target Alle CCR4 (Mogamulizumab Biosimilar) Produkte
    CCR4 (Mogamulizumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 1
    • 1
    Kaninchen
    Klonalität
    • 1
    • 1
    Chimeric
    Konjugat
    • 2
    Dieser CCR4 (Mogamulizumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 1
    • 1
    Depletion (Dep)
    Verwendungszweck
    Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa
    Spezifität
    This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
    Produktmerkmale

    Original Species of Ab: Human

    Original Format of Ab: IgG1

    Aufreinigung
    Protein A affinity purified
    Immunogen
    This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
    Klon
    KW-0761
    Isotyp
    IgG kappa
  • Applikationshinweise
    The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
    Kommentare

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    CCR4 (Mogamulizumab Biosimilar)
    Abstract
    CCR4 (Mogamulizumab Biosimilar) Produkte
    Substanzklasse
    Biosimilar
    Hintergrund
    CD194, CKR-4, CCR-4, CCR4, K5-5
    UniProt
    P51679
Sie sind hier:
Kundenservice